Despite Inclusion Of Generics On China's Essential Drug List, Simcere's Leadership Will Keep Focus On Innovative Drugs

BEIJING - While partly attributing an earnings slide, and a dip in sales of its top-selling biopharmaceutical, to the worldwide economic crisis, the leadership of Simcere Pharmaceutical also ruled out the possibility that the inclusion of a wide range of the company's products on China's new Essential Drug List could help trigger a rapid rebound